Alnylam Pharmaceuticals(ALNY)

CAMBRIDGE, MAPharmaceutical3 H-1B visas (FY2023)

Focus: Alnylam is a public specialty pharma company pioneering RNAi therapeutics across gene therapy and neurology, with four marketed products generating $1.8B in FY 2025 revenue.

Gene Therapy Neurology

Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Total Funding

$250M

Open Jobs

10+10 this month

Growing — net +10 jobs in 30d

10 jobs added vs 0 removed. Steady team buildout.

Should You Work at Alnylam Pharmaceuticals?

AI assessment

Strong fit for RNAi specialists and pipeline-focused scientists, but revenue concentration and burn rate warrant caution for those prioritizing stability.

Why Work Here

Leadership position in RNAi technology platform with deep scientific moat and validated clinical efficacy across multiple indications
Strong revenue growth (80% YoY from FY2024 to FY2025) and 55% R&D intensity signal sustained investment in pipeline innovation

Data completeness

6/9 — Partial

Company HealthStrong

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$1.8B

Key Products

AMVUTTRA

Transthyretin Amyloidosis with Cardiomyopathy

$67M Part D

Peak

Help build intelligence for Alnylam Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

ATTR Prevalence and Prediction Study

Transthyretin Amyloidosis

N/A

TRAMmoniTTR TTR Screening and Monitoring Study

Transthyretin Amyloidosis

N/A

Patisiran Pregnancy Surveillance Program

Hereditary Transthyretin-mediated (hATTR) Amyloidosis

N/A

Patisiran ATTRv Effectiveness Study

Hereditary Transthyretin-mediated (ATTRv) Amyloidosis

N/A

99mTc-pyrophosphate Scintigraphy

Transthyretin Amyloidosis

N/A

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis

Transthyretin-Mediated Amyloidosis

N/A

Clinical Trials (1)

NCT04561518ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

N/A

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Acute Hepatic Porphyria

N/A

Clinical Trials (1)

NCT04883905ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

N/A

INSIGHT-AHP Acute Hepatic Porphyria Prevalence Study

Acute Hepatic Porphyria

N/A

TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positiv

Transthyretin Amyloidosis

N/A

Clinical Trials (1)

NCT03237494TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects

N/A

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Re

Transthyretin Amyloidosis With Cardiomyopathy

N/A

Clinical Trials (1)

NCT07358078DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

N/A

No intervention. Retrospective observation only.

Chronic Inflammatory Demyelinating Polyneuropathy

N/A

Clinical Trials (1)

NCT05940922RWE-based Treatment Patterns and Outcomes in CIDP

N/A

DISCOVERY Cardiac Amyloidosis Prevalence Study

Familial Amyloidotic Cardiomyopathy (FAC)

N/A

ALECT2 Disease Natural History Study

Leukocyte Chemotactic Factor 2 Amyloidosis

N/A

ConTTRibute ATTR Amyloidosis Registry

Transthyretin-Mediated Amyloidosis

N/A

TTR Amyloidosis Biomarker Study

Hereditary Amyloidosis, Transthyretin-Related

N/A

INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients Wit

Acute Hepatic Porphyria

N/A

Clinical Trials (1)

NCT03547297INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP

N/A

EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

Acute Hepatic Porphyria

N/A

Clinical Trials (1)

NCT02240784EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

N/A

Natural History of Acute Hepatic Porphyria

Acute Hepatic Porphyria

N/A

A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease

Amyloidosis

N/A

Clinical Trials (1)

NCT03774784A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease

N/A

Standard of Care

Hereditary Amyloidosis, Transthyretin-Related

N/A

Clinical Trials (3)

NCT05103332Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

Phase 2

NCT06272487Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

Givosiran (Acute Hepatic Porphyria registry)

Acute Hepatic Porphyria

N/A

BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

Primary Hyperoxaluria Type 1

N/A

Clinical Trials (1)

NCT04982393BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

N/A

CIDP treatment patterns and outcomes

Chronic Inflammatory Demyelinating Polyneuropathy

N/A

ALN-GO1 (Primary Hyperoxaluria registry)

Primary Hyperoxaluria Type 1

N/A

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac

Familial Amyloidotic Cardiomyopathy (FAC)

N/A

Clinical Trials (1)

NCT02252653DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

N/A

DemonsTTRate ATTR-CM Registry

Transthyretin Amyloidosis With Cardiomyopathy

N/A

ALN-TTRSC04

Transthyretin-Mediated Amyloidosis

Phase 1

Clinical Trials (1)

NCT05661916A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects

Phase 1

ALN-TTR02

TTR-mediated Amyloidosis

Phase 1

Clinical Trials (5)

NCT02510261The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Phase 3

NCT01960348APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

ALN-4915

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT07535606A Study to Evaluate ALN-4915 in Adult Healthy Volunteers

Phase 1

ALN-AGT01 RVR

Hypertension

Phase 1

ALN-PCSSC

Hypercholesterolemia

Phase 1

Clinical Trials (1)

NCT02314442A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Phase 1

ALN-HTT02

Huntington's Disease

Phase 1

Clinical Trials (1)

NCT06585449A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

Phase 1

ALN-BCAT

Advanced Hepatocellular Carcinoma

Phase 1

Clinical Trials (1)

NCT06600321A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Phase 1

ALN-5288

Alzheimer's Disease

Phase 1

Clinical Trials (1)

NCT07214727A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Phase 1

ALN-HBV

Chronic Hepatitis B

Phase 1

Clinical Trials (1)

NCT02826018A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection

Phase 1

ATTR Algorithm Identification Study

Transthyretin Amyloidosis

Phase 1

Computer algorithm for ATTR

Transthyretin Amyloidosis

Phase 1

Clinical Trials (1)

NCT04569903Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records

Phase 1

ALN-TTRSC02

Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)

Phase 1

Clinical Trials (1)

NCT02797847A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects

Phase 1

ALN-HSD

Nonalcoholic Steatohepatitis (NASH)

Phase 1

Clinical Trials (1)

NCT04565717A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

Phase 1

ALN-PCS02

Elevated LDL-Cholesterol (LDL-C)

Phase 1

Clinical Trials (1)

NCT01437059Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)

Phase 1

ALN-4285

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT07295717A Study to Evaluate ALN-4285 in Adult Healthy Volunteers

Phase 1

ALN-AAT

Antitrypsin Deficiency Liver Disease

Phase 1

Clinical Trials (1)

NCT02503683A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Phase 1

ALN-VSP02

Solid Tumors

Phase 1

Clinical Trials (2)

NCT00882180Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement

Phase 1

NCT01158079Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment

ALN-TTR01

Transthyretin Mediated Amyloidosis (ATTR)

Phase 1

Clinical Trials (1)

NCT01148953Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis

Phase 1

ALN-6222

Obesity

Phase 1

Clinical Trials (1)

NCT07624071A Study to Evaluate ALN-6222 in Participants With Obesity

Phase 1

ALN-6400

Hereditary Hemorrhagic Telangiectasia (HHT)

Phase 1/2

Clinical Trials (2)

NCT07575308HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

Phase 2

NCT06659640A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

ALN-CC5

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 1/2

Clinical Trials (1)

NCT02352493A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH

Phase 1/2

ALN-KHK

Type 2 Diabetes Mellitus (T2DM)

Phase 1/2

Clinical Trials (1)

NCT05761301A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

Phase 1/2

ALN-2232

Obesity

Phase 1/2

Clinical Trials (1)

NCT07463846A Study to Evaluate ALN-2232 in Participants With Obesity

Phase 1/2

ALN-AAT02

ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Phase 1/2

Clinical Trials (1)

NCT03767829A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Phase 1/2

Alnylam Pharmaceuticals(ALNY)

Should You Work at Alnylam Pharmaceuticals?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (4)

Key Products by Revenue

Other Products (1)

Pipeline & Clinical Trials

Recent News · Alnylam Pharmaceuticals(10)

Open Jobs (10)

Mattie Test Job

Scientist

Software Engineer

Registered Nurse

Executive

Retail Sales Associate

Assembler

Customer Service Representative

Manufacturing Engineer

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Private Funding (SEC Form D)